Lifitegrast: A novel drug for treatment of dry eye disease. - Abstract - Europe PMC
Mechanism of Action | Xiidra® (lifitegrast ophthalmic solution) 5%
Mechanism of Action | Xiidra® (lifitegrast ophthalmic solution) 5%
A Review of Topical Cyclosporine A Formulations—A Disease-Modify | OPTH
Untitled
A Review of Topical Cyclosporine A Formulations—A Disease-Modify | OPTH
An Engineered Contact Lens for Passive and Sustained Release of Lifitegrast, an Anti-Dry Eye Syndrome Drug | bioRxiv
Targeting Ocular Disorders Sept. Boston - Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
U.S. FDA Grants Priority Review to Lifitegrast NDA for the Treatment of Dry Eye Disease in Adults - Neuroptis Dry Eye Project with ML 7 (Myosin Light Chain Inhibitor)
Ophthalmology Management - SIMPLIFYING THE COMPLICATED: OCULAR SURFACE DISEASE AND THE KISS PRINCIPLE
DRY EYE DISEASE
An Engineered Contact Lens for Passive and Sustained Release of Lifitegrast, an Anti-Dry Eye Syndrome Drug
The Definitive Dry Eye Update: Lab
Xiidra (lifitegrast ophthalmic solution) for the Treatment of Dry Eye Disease - Clinical Trials Arena
Lifitegrast ophthalmic solution in the treatment of signs and symptoms | OPTH
LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease
CRSToday | Dry Eye Disease: Integrating Old and New Therapies
Lifitegrast - Wikiwand
Deeper Insight THERAPY 5 - ANTI-INFLAMMATORY Therapy — Ocular Surface Center Berlin
These highlights do not include all the information needed to use XIIDRA safely and effectively. See full prescribing information for XIIDRA. XIIDRA® (lifitegrast ophthalmic solution), for topical ophthalmic useInitial U.S. Approval: 2016
lifitegrast | 1025967-78-5
The Development of Lifitegrast to Treat Dry Eye Syndrome • iBiology
